Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

393 related articles for article (PubMed ID: 19147568)

  • 1. Targeting ornithine decarboxylase impairs development of MYCN-amplified neuroblastoma.
    Rounbehler RJ; Li W; Hall MA; Yang C; Fallahi M; Cleveland JL
    Cancer Res; 2009 Jan; 69(2):547-53. PubMed ID: 19147568
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ODC1 is a critical determinant of MYCN oncogenesis and a therapeutic target in neuroblastoma.
    Hogarty MD; Norris MD; Davis K; Liu X; Evageliou NF; Hayes CS; Pawel B; Guo R; Zhao H; Sekyere E; Keating J; Thomas W; Cheng NC; Murray J; Smith J; Sutton R; Venn N; London WB; Buxton A; Gilmour SK; Marshall GM; Haber M
    Cancer Res; 2008 Dec; 68(23):9735-45. PubMed ID: 19047152
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Key role for p27Kip1, retinoblastoma protein Rb, and MYCN in polyamine inhibitor-induced G1 cell cycle arrest in MYCN-amplified human neuroblastoma cells.
    Wallick CJ; Gamper I; Thorne M; Feith DJ; Takasaki KY; Wilson SM; Seki JA; Pegg AE; Byus CV; Bachmann AS
    Oncogene; 2005 Aug; 24(36):5606-18. PubMed ID: 16007177
    [TBL] [Abstract][Full Text] [Related]  

  • 4. DFMO/eflornithine inhibits migration and invasion downstream of MYCN and involves p27Kip1 activity in neuroblastoma.
    Koomoa DL; Geerts D; Lange I; Koster J; Pegg AE; Feith DJ; Bachmann AS
    Int J Oncol; 2013 Apr; 42(4):1219-28. PubMed ID: 23440295
    [TBL] [Abstract][Full Text] [Related]  

  • 5. AMXT-1501, a novel polyamine transport inhibitor, synergizes with DFMO in inhibiting neuroblastoma cell proliferation by targeting both ornithine decarboxylase and polyamine transport.
    Samal K; Zhao P; Kendzicky A; Yco LP; McClung H; Gerner E; Burns M; Bachmann AS; Sholler G
    Int J Cancer; 2013 Sep; 133(6):1323-33. PubMed ID: 23457004
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting ornithine decarboxylase in Myc-induced lymphomagenesis prevents tumor formation.
    Nilsson JA; Keller UB; Baudino TA; Yang C; Norton S; Old JA; Nilsson LM; Neale G; Kramer DL; Porter CW; Cleveland JL
    Cancer Cell; 2005 May; 7(5):433-44. PubMed ID: 15894264
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hsp90 inhibition increases p53 expression and destabilizes MYCN and MYC in neuroblastoma.
    Regan PL; Jacobs J; Wang G; Torres J; Edo R; Friedmann J; Tang XX
    Int J Oncol; 2011 Jan; 38(1):105-12. PubMed ID: 21109931
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combined IFN-gamma and retinoic acid treatment targets the N-Myc/Max/Mad1 network resulting in repression of N-Myc target genes in MYCN-amplified neuroblastoma cells.
    Cetinkaya C; Hultquist A; Su Y; Wu S; Bahram F; Påhlman S; Guzhova I; Larsson LG
    Mol Cancer Ther; 2007 Oct; 6(10):2634-41. PubMed ID: 17938259
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ornithine decarboxylase inhibition by alpha-difluoromethylornithine activates opposing signaling pathways via phosphorylation of both Akt/protein kinase B and p27Kip1 in neuroblastoma.
    Koomoa DL; Yco LP; Borsics T; Wallick CJ; Bachmann AS
    Cancer Res; 2008 Dec; 68(23):9825-31. PubMed ID: 19047162
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cyclin-Dependent Kinase Inhibitor AT7519 as a Potential Drug for MYCN-Dependent Neuroblastoma.
    Dolman ME; Poon E; Ebus ME; den Hartog IJ; van Noesel CJ; Jamin Y; Hallsworth A; Robinson SP; Petrie K; Sparidans RW; Kok RJ; Versteeg R; Caron HN; Chesler L; Molenaar JJ
    Clin Cancer Res; 2015 Nov; 21(22):5100-9. PubMed ID: 26202950
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synergistic drug combination GC7/DFMO suppresses hypusine/spermidine-dependent eIF5A activation and induces apoptotic cell death in neuroblastoma.
    Schultz CR; Geerts D; Mooney M; El-Khawaja R; Koster J; Bachmann AS
    Biochem J; 2018 Jan; 475(2):531-545. PubMed ID: 29295892
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Phase I Trial of DFMO Targeting Polyamine Addiction in Patients with Relapsed/Refractory Neuroblastoma.
    Saulnier Sholler GL; Gerner EW; Bergendahl G; MacArthur RB; VanderWerff A; Ashikaga T; Bond JP; Ferguson W; Roberts W; Wada RK; Eslin D; Kraveka JM; Kaplan J; Mitchell D; Parikh NS; Neville K; Sender L; Higgins T; Kawakita M; Hiramatsu K; Moriya SS; Bachmann AS
    PLoS One; 2015; 10(5):e0127246. PubMed ID: 26018967
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transcriptional repression of SKP2 is impaired in MYCN-amplified neuroblastoma.
    Muth D; Ghazaryan S; Eckerle I; Beckett E; Pöhler C; Batzler J; Beisel C; Gogolin S; Fischer M; Henrich KO; Ehemann V; Gillespie P; Schwab M; Westermann F
    Cancer Res; 2010 May; 70(9):3791-802. PubMed ID: 20424123
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Eflornithine (DFMO) prevents progression of pancreatic cancer by modulating ornithine decarboxylase signaling.
    Mohammed A; Janakiram NB; Madka V; Ritchie RL; Brewer M; Biddick L; Patlolla JM; Sadeghi M; Lightfoot S; Steele VE; Rao CV
    Cancer Prev Res (Phila); 2014 Dec; 7(12):1198-209. PubMed ID: 25248858
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Next-generation RNA sequencing reveals differential expression of MYCN target genes and suggests the mTOR pathway as a promising therapy target in MYCN-amplified neuroblastoma.
    Schramm A; Köster J; Marschall T; Martin M; Schwermer M; Fielitz K; Büchel G; Barann M; Esser D; Rosenstiel P; Rahmann S; Eggert A; Schulte JH
    Int J Cancer; 2013 Feb; 132(3):E106-15. PubMed ID: 22907398
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of human ornithine decarboxylase activity by enantiomers of difluoromethylornithine.
    Qu N; Ignatenko NA; Yamauchi P; Stringer DE; Levenson C; Shannon P; Perrin S; Gerner EW
    Biochem J; 2003 Oct; 375(Pt 2):465-70. PubMed ID: 12859253
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Polyamine synthesis as a target of
    Bachmann AS; Geerts D
    J Biol Chem; 2018 Nov; 293(48):18757-18769. PubMed ID: 30404920
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The MYCN oncoprotein as a drug development target.
    Lu X; Pearson A; Lunec J
    Cancer Lett; 2003 Jul; 197(1-2):125-30. PubMed ID: 12880971
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Translational development of difluoromethylornithine (DFMO) for the treatment of neuroblastoma.
    Bassiri H; Benavides A; Haber M; Gilmour SK; Norris MD; Hogarty MD
    Transl Pediatr; 2015 Jul; 4(3):226-38. PubMed ID: 26835380
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Polyamine Antagonist Therapies Inhibit Neuroblastoma Initiation and Progression.
    Evageliou NF; Haber M; Vu A; Laetsch TW; Murray J; Gamble LD; Cheng NC; Liu K; Reese M; Corrigan KA; Ziegler DS; Webber H; Hayes CS; Pawel B; Marshall GM; Zhao H; Gilmour SK; Norris MD; Hogarty MD
    Clin Cancer Res; 2016 Sep; 22(17):4391-404. PubMed ID: 27012811
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.